| 查看: 1811 | 回复: 101 | |||
[交流]
【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果
|
|||
|
Teva 对临床3期评估了对于哮喘患者干粉吸入器 (MDPIs)吸入Fluticasone Propionate /Salmeterol和多剂量Fluticasone Propionate 的实验效果，实验数据很好。研究表明通过使用干粉吸入器 (MDPI)，低剂量与安慰剂相比具有更大的效能，结果展示 Teva 扩大呼吸的研发能力和支持其核心，呼吸驱动MDPI平台的发展。最初的结果显示fluticasone propionate/salmeterol MDPI的不良事件可以和fluticasone propionate治疗和安慰剂媲美。 相关阅读： Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. “These data support Teva’s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.” Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals. “We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.” Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016. |
回复此楼» 猜你喜欢
有没有接收比较快的sci期刊呀，最好在一个月之内的，研三孩子求毕业
已经有6人回复
-
求调剂
已经有6人回复
-
307中医考研调剂
已经有9人回复
-
327求调剂
已经有30人回复
-
294求调剂
已经有15人回复
-
0854求调剂
已经有27人回复
-
300求调剂
已经有12人回复
-
291求调剂
已经有10人回复
-
一志愿沪9，326求生物学调剂
已经有12人回复
-
生物学调剂
已经有10人回复
» 抢金币啦！回帖就可以得到:
-
伦敦布鲁内尔大学诚招国家公派读博，联合培养博士生，物流供应链方向
+1/83
-
长江大学化工学院化工学硕、专硕最后一批调剂（理学、工学均可）
+1/80
-
安心播种，静待花开
+1/67
-
江西科技师范大学086生物与医药
+1/38
-
盐城师范学院生物与医药（生物技术与工程领域）还有调剂名额
+1/36
-
北华大学 08代码 调剂虚位以待
+1/35
-
广西科技大学化工专业现仍有较多调剂指标，欢迎符合条件的同学申请调剂
+1/32
-
还有名额！！辽石化新材料学院材料专业调剂 理转工 / 学专互调
+1/31
-
粤港澳大湾区量子中心与南方科技大学联合招收2026级博士生（材料、凝聚态物理方向）
+1/16
-
佛山大学动物科技学院2026年硕士研究生招生调剂公告（第三批）
+1/8
-
北京理工大学（珠海）招收智能科学与技术方向26级博士
+1/7
-
东北林业大学（211，双一流）宋老师招收高分子、化学、生物质材料等方向博士研究生2名
+1/7
-
湖南理工大学 化学、化工调剂指标充足，录取率高，调剂系统最后一次开放
+1/6
-
青岛科技大学高分子学院硕士招生
+1/6
-
重庆三峡科技大学电磁场与微波技术专业接收调剂，考数二可调，系统4月13日开放
+1/5
-
山东大学集成电路学院招博士了
+1/5
-
南京林业大学-国家级青年人才团队 诚聘青年教授、博士后等青年才俊
+1/5
-
知名外资仪器厂家急招Application Scientist-成都上海
+1/1
-
郑州大学物理学院倪佩楠教授课题组诚邀博士后、青年教师及副教授加盟
+1/1
-
招07理学调剂生，剩余2个名额
+1/1
★
药渡(金币+1): 谢谢参与
药渡(金币+1): 谢谢参与
|
本帖内容被屏蔽 |
14楼2015-11-20 16:01:12
简单回复
sxln2楼
2015-11-20 15:48
回复
药渡(金币+1): 谢谢参与
laom20133楼
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
。 发自小木虫Android客户端
天涯20126楼
2015-11-20 15:51
回复
药渡(金币+1): 谢谢参与
skyish7楼
2015-11-20 15:52
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:54
回复
药渡(金币+1): 谢谢参与
dmbb9楼
2015-11-20 15:57
回复
药渡(金币+1): 谢谢参与
江南的竹10楼
2015-11-20 15:58
回复
药渡(金币+1): 谢谢参与
。 [ 发自小木虫客户端 ]
chenchenyf11楼
2015-11-20 15:59
回复
药渡(金币+1): 谢谢参与
xiejiaf12楼
2015-11-20 16:00
回复
药渡(金币+1): 谢谢参与
feiyief13楼
2015-11-20 16:01
回复
药渡(金币+1): 谢谢参与
mhycpxir15楼
2015-11-20 16:01
回复
药渡(金币+1): 谢谢参与
irshvj16楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
kolimm17楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
祝福
am435918楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
wblxcs19楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
祝福
wnotffisg20楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
祝福
ahsjlyu21楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
.
keoxri22楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
vrxcyvkss23楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
,
ooxmfc24楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
ucmxjl25楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
,
bincmq26楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
祝福
fqmkia27楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
wxubpn28楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
祝福
iygbojqj29楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
sjtdeud30楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
shsvoy31楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
cmyfna32楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
sgadsdkc33楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
,
quainyni34楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
wbwwrs35楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
祝福
yuduoj36楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
支持
ofresq37楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
.
tanmingp38楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
qdjoupudwqx39楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
,
qyoycw40楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
fangfengw41楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
祝福
virologik42楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
liufeic43楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
xiachaz44楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
hodydo45楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
zhangfangp46楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
hudouz47楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
祝福
ffwmeg48楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
.
yushat49楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
qiyingy50楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
支持
